This is an aggregated industry headline. Read the full story at BioPharma Dive →
Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection
The agency took another step toward clearing a backlog of Makary-era rejections that appeared to contradict earlier agreements with drugmakers.
By BioPharma Dive
· Jun 22, 2026
· via BioPharma Dive
Image: BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Amid efforts in Germany to retool the country's drug spending, the U.S. is launching an investigation into wha…
The WeekFierceBiotech ↗
Exelixis' next franchise drug, zanzalintinib, has hit a clinical setback, although at least two groups of anal…
The WeekBriefing
China grants CARsgen approval for a Claudin18.2-targeted therapy, marking the first CAR-T authorized for solid…